A Phase I Open-Label Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Subtype C gp140 Vaccine With MF59 Adjuvant in Healthy, HIV-1 Uninfected Adult Participants Previously Primed or Unprimed With HIV-1 Subtype B Envelope Subunit Vaccines With MF59.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs HIV gp140 vaccine (Primary) ; MF 59
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 31 Mar 2017 Biomarkers information updated
- 23 Aug 2013 Planned End Date added to 1 Jan 2015 as reported by ClinicalTrials.gov.
- 23 Aug 2013 Company added as trial sponsor and additional lead trial centre identified as reported by ClinicalTrials.gov.